Liu B A, Mittmann N, Knowles S R, Shear N H
Division of Clinical Pharmacology, University of Toronto, Ont.
CMAJ. 1996 Sep 1;155(5):519-27.
To review reported cases of hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with the use of selective serotonin reuptake inhibitors (SSRIs).
A search of MEDLINE for reports of hyponatremia and SIADH associated with the use of fluoxetine, fluvoxamine, paroxetine or sertraline published between January 1980 and May 1995. Unpublished reports of cases were requested from the pharmaceutical industry, the Ontario Medical Association, the Health Protection Branch of Health Canada, the US Food and Drug Administration and the World Health Organization.
Spontaneous reports from postmarketing surveillance.
A total of 736 cases of hyponatremia [corrected] and SIADH associated with SSRI use were reported. Fluoxetine was involved in 554 (75.3%) of the cases, paroxetine in 91 (12.4%), sertraline in 86 (11.7%) and fluvoxamine in 11 (1.5%). Reports of 30 cases were published. The remaining 706 cases were reported to monitoring bodies and the pharmaceutical industry. According to information in the published reports, the median time to onset of hyponatremia was 13 days (range 3 to 120 days). Most (83%) of the published cases involved patients 65 years of age or more, as compared with 74% of the unpublished cases.
Elderly people may be at increased risk for hyponatremia associated with SSRI use. Physicians caring for elderly patients should be aware of this potentially serious but reversible adverse effect. Further research is required to determine the incidence of this adverse effect, the relative risk of hyponatremia and SIADH in different age groups and the risk associated with different SSRI drugs.
回顾报道的与使用选择性5-羟色胺再摄取抑制剂(SSRI)相关的低钠血症及抗利尿激素分泌异常综合征(SIADH)病例。
检索1980年1月至1995年5月期间发表的关于与使用氟西汀、氟伏沙明、帕罗西汀或舍曲林相关的低钠血症和SIADH报道。向制药行业、安大略省医学协会、加拿大卫生部健康保护局、美国食品药品管理局和世界卫生组织索要未发表的病例报告。
上市后监测的自发报告。
共报道了736例与使用SSRI相关的低钠血症[校正后]和SIADH病例。其中554例(75.3%)与氟西汀有关,91例(12.4%)与帕罗西汀有关,86例(11.7%)与舍曲林有关,11例(1.5%)与氟伏沙明有关。30例病例报告已发表。其余706例报告给了监测机构和制药行业。根据已发表报告中的信息,低钠血症发病的中位时间为13天(范围3至120天)。大多数(83%)已发表病例涉及65岁及以上患者,未发表病例中这一比例为74%。
老年人使用SSRI时发生低钠血症的风险可能增加。照顾老年患者的医生应意识到这种潜在的严重但可逆的不良反应。需要进一步研究以确定这种不良反应的发生率、不同年龄组低钠血症和SIADH的相对风险以及与不同SSRI药物相关的风险。